Browse Category

Mergers & Acquisitions 12 November 2025 - 18 November 2025

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions include a 40‑year tranche initially talked around ~125 bps over Treasuries, according to Bloomberg reporting on the transaction. A separate Reuters alert flagged a seven‑part notes offering in a fresh SEC filing, with sizing to be finalized at pricing. Together, the moves point to active balance‑sheet management following the Metsera close. Bloomberg Law+1
18 November 2025
·····
Blue Owl’s BDC Shake‑Up (Nov. 17, 2025): OBDC–OBDC II Merger Puts ~20% Haircut on the Table for Retail Holders—But Double‑Digit Yields Lure Value Buyers

Blue Owl’s BDC Shake‑Up (Nov. 17, 2025): OBDC–OBDC II Merger Puts ~20% Haircut on the Table for Retail Holders—But Double‑Digit Yields Lure Value Buyers

Summary: Blue Owl Capital is moving to fold its private Blue Owl Capital Corporation II into the listed Blue Owl Capital Corporation. Because OBDC stock trades below its reported net asset value, today’s pricing implies roughly a 20% value hit for OBDC II investors at closing—though the combined BDC would be larger, more liquid and, at today’s price, offers a double‑digit dividend yield. Blue Owl Capital Corporation+2Blue Owl Capital Corporation+2
17 November 2025
·
Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics Inc. is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right structure that could unlock additional upside over the coming decade. Repare Therapeutics+1
17 November 2025
·
Ashurst–Perkins Coie Merger Creates $2.7 Billion Transatlantic Megafirm in Big Law Shake-Up

Ashurst–Perkins Coie Merger Creates $2.7 Billion Transatlantic Megafirm in Big Law Shake-Up

LONDON / SEATTLE — November 17, 2025 — London-headquartered Ashurst and US firm Perkins Coie have agreed to merge in a landmark transatlantic deal that will create a top‑20 global law firm with around 3,000 lawyers and annual revenue of about $2.7 billion. Operating under the new brand Ashurst Perkins Coie, the combined outfit will span 52 offices in 23 countries, cementing its status as one of the largest law firms in the world. Reuters+2Legal Cheek+2
17 November 2025
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race.
17 November 2025
···
TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

PARIS — November 17, 2025. TotalEnergies has agreed to acquire a 50% stake in Energetický a průmyslový holding’s flexible power generation platform in a €5.1 billion, all‑stock transaction. The deal creates a 50/50 joint venture spanning more than 14 gigawatts of gas‑fired, biomass and battery assets across Italy, the UK & Ireland, the Netherlands and France, with closing targeted for mid‑2026 pending approvals. EPH will be paid in newly issued TotalEnergies shares and become a meaningful shareholder in the French energy major. TotalEnergies.com+1
17 November 2025
····
Warner Bros. Discovery (WBD) Stock Climbs as Paramount, Comcast and Netflix Line Up Bids in High‑Stakes Auction – November 14, 2025

Warner Bros. Discovery (WBD) Stock Climbs as Paramount, Comcast and Netflix Line Up Bids in High‑Stakes Auction – November 14, 2025

Warner Bros. Discovery, Inc. moved back into the spotlight on Friday, November 14, 2025, as a potential sale of all or part of the media giant appeared to crystallize into a three‑way contest between Paramount Skydance, Comcast and Netflix. The growing prospect of a bidding war sent WBD shares higher and intensified scrutiny of the company’s strategy, leadership and balance sheet. TradingView+3Sports Business Journal+3The Wall Street Journal+3
14 November 2025
·····
Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor, Inc. returned to investors’ good graces on Friday after Mizuho upgraded the online travel company and lifted its price target, signaling Wall Street is starting to warm to an aggressive restructuring that includes layoffs, a Viator merger and a deeper bet on AI-powered travel experiences. Investing.com+1
14 November 2025
···
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN shares rocketing higher and triggered immediate legal and regulatory attention, making this one of the most closely watched biotech deals of the day. GlobeNewswire
13 November 2025
···
Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer stock is trading higher today as investors digest a fresh batch of headlines: a planned sale of the company’s remaining stake in Covid-19 vaccine partner BioNTech, ongoing reaction to its $10 billion Metsera obesity-drug deal, and renewed debate around whether PFE’s rich dividend compensates for its strategic risks.
13 November 2025
···
CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

Creative Media & Community Trust Corporation said today it has signed a definitive agreement to sell its lending division to PG FR Holding, LLC, an affiliate of the Atlanta‑based Peachtree Group. The deal value is approximately $44 million and is expected to generate about $31 million in net cash to CMCT after debt paydowns and transaction costs, pending closing conditions. Business Wire
12 November 2025
·
1 … 12 13 14 15 16 … 20
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY ON PULLBACK

Microsoft

NASDAQ: MSFT 94 / 100
#2 BUY

L3Harris Technologies

NYSE: LHX 90 / 100
#3 BUY

Xylem

NYSE: XYL 89 / 100
#4 BUY IN TRANCHES

Lam Research

NASDAQ: LRCX 87 / 100
#5 BUY ON WEAKNESS

GE HealthCare

NASDAQ: GEHC 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.